Ignite Creation Date:
2025-12-24 @ 9:09 PM
Ignite Modification Date:
2026-02-23 @ 12:21 PM
Study NCT ID:
NCT05683704
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2023-01-13
First Post:
2023-01-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
ALTN-AK105-II-05
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None